Business
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
SHANGHAI & CAMBRIDGE, Mass., April 01, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab’s investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen’s IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-stage small cell lung cancer
About this update from Zai Lab Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":224,"url":"https://media.zenfs.com/en/business-wire.com/eb70225dcc17434bd619de7fb040e0f9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XINndWY8X28AuR9M4rduHw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ0OA--/https://media.zenfs.com/en/business-wire.com/eb70225dcc17434bd619de7fb040e0f9","width":480,"height":224}},"lazy":false},{"type":"text","content":"- Collaboration with Amgen to explore the clinical potential of Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen’s IMDELLTRA®","length":156,"tagName":"p","attribs":{}},{"type":"text","content":"- Amgen to sponsor and lead global Phase 1b study; Zai Lab to retain full ownership of zocilurtatug pelitecan","length":109,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI & CAMBRIDGE, Mass., April 01, 2026--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a global clinical trial collaboration with Amgen Inc. (NASDAQ: AMGN) to evaluate Zai Lab’s investigational delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci, formerly ZL-1310), in combination with Amgen’s IMDELLTRA® (tarlatamab-dlle), a DLL3-targeting Bispecific T-cell Engager (BiTE®) therapy in patients with extensive-stage small cell lung cancer (ES-SCLC).","length":532,"tagName":"p"},{"type":"text","content":"As part of this collaboration agreement, Amgen will sponsor a global Phase 1b study to evaluate the safety and efficacy of zoci in combination with IMDELLTRA® in patients with ES-SCLC. Zai Lab will retain full ownership of zoci and will supply Amgen with the study drug.","length":270,"tagName":"p"},{"type":"text","content":""In combination, this dual-targeting strategy has the potential to increase the rate and deepen responses both systemically and, in the brain, address resistance pathways, and unlock new treatment paradigms for patients with small cell lung cancer," said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. "These two approaches leverage complementary mechanisms — our ADC delivers a potent cytotoxic payload directly to DLL3-expressing tumor cells, while the T-cell engager is designed to activate T-cells b...